Further, riluzole is a known substrate of the p-glycoprotein system, thus limiting its blood-brain barrier penetration (augmenting the challenges of assuring appropriate therapeutic dose on target), which could be further exacerbated by evidence showing that p-glycoprotein system is upregulated in ALS [21–23]. This evidence concerns the gene ABCB1 and amyotrophic lateral sclerosis.